Oculis (NASDAQ:OCS) Given New $41.00 Price Target at Robert W. Baird

Oculis (NASDAQ:OCS) had its price target hoisted by Robert W. Baird from $37.00 to $41.00 in a research report released on Thursday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other brokerages have also commented on OCS. Chardan Capital reiterated a “buy” rating and set a $28.00 price target on shares of Oculis in a report on Thursday. HC Wainwright cut their target price on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday.

Oculis Price Performance

Shares of OCS opened at $18.70 on Thursday. The business has a 50-day simple moving average of $20.86 and a two-hundred day simple moving average of $16.88. Oculis has a 12-month low of $10.55 and a 12-month high of $23.08. The stock has a market cap of $757.42 million, a PE ratio of -9.69 and a beta of 0.02. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. Analysts anticipate that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of institutional investors have recently modified their holdings of OCS. abrdn plc lifted its holdings in Oculis by 23.0% in the fourth quarter. abrdn plc now owns 1,009,424 shares of the company’s stock valued at $17,150,000 after buying an additional 188,871 shares during the period. Geode Capital Management LLC raised its position in shares of Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after acquiring an additional 1,800 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Oculis in the 4th quarter valued at about $225,000. Bellevue Group AG bought a new stake in shares of Oculis during the 4th quarter valued at about $170,000. Finally, Bank of America Corp DE grew its stake in Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after purchasing an additional 10,667 shares during the period. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.